Difference between revisions of "DZI20-239-Case-2"

From MGH Learn Pathology
(Automatic edit to upgrade to new templates)
(Updating subject, access, and performer)
Line 13: Line 13:
 
WBC 21.02*; HGB 7.3*; HCT 22.7*; PLT 138*; MCV 96.
 
WBC 21.02*; HGB 7.3*; HCT 22.7*; PLT 138*; MCV 96.
 
DIFF: Neutr 64; Lymph 12; Monos 1; Basos 1; Bands 1; Metas 2; Myelos 16; Other WBCs 3.
 
DIFF: Neutr 64; Lymph 12; Monos 1; Basos 1; Bands 1; Metas 2; Myelos 16; Other WBCs 3.
|subject=public
+
|subject=MGH
|performer=Vn048
+
|performer=VN048
 
|authoredOn=November 25, 2020 10:19:55 PM
 
|authoredOn=November 25, 2020 10:19:55 PM
 
|requester=Vn048
 
|requester=Vn048
 
|sequence=2
 
|sequence=2
 +
|access=public
 
}}
 
}}
 
{{Media
 
{{Media

Revision as of 15:00, June 21, 2022

DZI20-239-Case-2
68 yo man presenting to the ED with acute chest pain c/f aortic dissection noted to have an abnormal CBC and smear

WBC 21.02*; HGB 7.3*; HCT 22.7*; PLT 138*; MCV 96.

DIFF: Neutr 64; Lymph 12; Monos 1; Basos 1; Bands 1; Metas 2; Myelos 16; Other WBCs 3.
One year reported history of ET never confirmed by bone marrow review on hydroxyurea. The current findings are suggestive of either progression of the disease or question the original diagnosis. If this was the diagnostic specimen MDS/MPN overlap would be a consideration.
December 2, 2020